Oryzon Genomics
ORY.MCORY.MC · Stock Price
Historical price data
Overview
Oryzon Genomics is a Spanish biotech focused on developing personalized epigenetic medicines for cancer and CNS diseases. Its core achievement is building a robust clinical pipeline anchored by iadademstat, an LSD1 inhibitor in Phase II for AML, and vafidemstat for neuropsychiatric indications. The company's strategy involves expanding patent protection for key drug combinations and advancing its integrated discovery-to-early-commercialization platform to create targeted therapeutics with companion diagnostics.
Technology Platform
Integrated epigenetic platform for target and biomarker discovery, focused on key regulators like LSD1/KDM1A, enabling the development of targeted small molecule modulators and companion diagnostics.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Iadademstat + Paclitaxel | Small-cell Lung Cancer | Phase 2 | |
| vafidemstat + Placebo | Borderline Personality Disorder | Phase 2 | |
| ORY-2001 Low dose + ORY-2001 High dose + Placebo | Mild to Moderate Alzheimer's Disease | Phase 2 | |
| Iadademstat + Atezolizumab | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | |
| Azacitidine + Iadademstat + Venetoclax | Acute Myeloid Leukemia | Phase 1 |
Funding History
2
Company Timeline
Founded in Barcelona, Spain
Series A: $10.0M
Initial Public Offering